Amgen’s AMG 510, the first therapy to reach clinical trials that inhibits a mutant KRAS protein, has demonstrated promising safety and efficacy results based on…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.